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S362 Poster Session IIniche demonstrated exacerbated loss of ISC in IL-22 KO mice dur-
ing GVHD.
In summary, IL-22 was produced post-BMT by host ILC that
were eliminated during GVHD, and IL-22 deficiency increased
GVHD morbidity and mortality. While IL-22 deficiency did not
significantly alter the donor immune response, it did lead to in-
creased GVHD pathology, loss of epithelial integrity, and loss of
ISC. IL-22 is thus critical for protection of host epithelium during
GVHD. This may be exploited in the future to reduce clinical
GVHD without limiting the curative potential of the transplant.427
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Introduction: We have recently established an immunodeficient
NOD/SCID/IL2Rgcnull (NSG) mouse model that allows the reli-
able engraftment of primary human acute myeloid leukemia
(AML) blasts, particularly those with FLT3-ITD mutations. We
now use these mice as a platform to evaluate the graft-versus-leuke-
mia (GvL) effect of human leukemia-reactive T cells in vivo. To sys-
tematically optimize essential parameters for survival and effector
function of human T cells in NSG mice, large numbers of AML-re-
active cytotoxic T lymphocytes (CTL) were generated in vitro by
stimulation of healthy donor CD8+ T cells with FLT3-ITD+ AML
blasts in either singleHLA-class I-mismatched orHLA-matched sit-
uations.
Methods: 5x10e5 AML blasts were injected into 6-8 week-old irra-
diated (150cGy) NSG mice to achieve 1-5% AML engraftment in
bone marrow (BM) within 18 days (d) resembling minimal residual
disease. Subsequently, 5x10e6 alloreactive CD8+ CTL expanded
over 14, 21, 28, and 56 d in vitro were transfused into mice to inves-
tigate differences in homing, survival, and GvL reactivity in vivo.
Controls included AML-engrafted mice without CTL as well as
mice receiving CTL of irrelevant antiviral specificity. All mice re-
ceived human interleukin (IL)2, IL7-Fc and IL15 at time of T cell
injection. AML-reactivity was analyzed in kinetic studies 2 h, 24 h,
48 h and 7 d after CTL transfer.
Results: We observed complete eradication of patient-derived
FLT3-ITD+ AML blasts in BM, spleen and peripheral blood of
mice one week after transfer of single locus HLA-B mismatched
CTL that had been cultured for 14, 21, or 28 d, respectively. In con-
trast, control mice showed 25-61% (median 35%) leukemia infiltra-
tion in BM. Kinetic analysis demonstrated almost complete AML
remission as early as 48 h after T cell transfer. Ex vivo analysis of
CTL re-isolated from murine spleens 24 and 48 h after injection
showed persistent reactivity to AML blasts, but not to NSG-derived
murine dendritic cells. Interestingly, CTL expanded over 56 d in vi-
tro appeared less capable to eradicate AML in vivo. Results were re-
producible in 2 different donor-patient pairs and, moreover, are in
line with ongiong studies in HLA-matched systems.
Conclusion: We show herein that NSG mice engrafted with pri-
mary human AML blasts can be successfully treated with human al-
loreactive CTL. The model will be further optimized to serve as
a general platform for testing the GvL effect of T cell grafts before
adoptive transfer into humans.428
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Bronchiolitis obliterans syndrome (BOS) after allogeneic
HSCT is a deadly manifestation of cGVHD. Current treatments
are inferior and yield transient responses with published overall
survival of 44% at 2 years. Although the pathogenesis of BOS af-
ter HSCT is unknown, a similar disease, BOS after lung trans-
plant is associated with elevated leukotriene levels. We present
preliminary results from a prospective, open label, phase II trial
testing the efficacy of montelukast, a leukotriene inhibitor, for
the treatment of BOS after HSCT. BOS diagnostic criteria in-
cluded: FEV1\75%, FEV1/VC \ 0.7 or air trapping on CT
and RV.120% or RV/TLC.120% in the absence of infection
and presence of another cGVHD manifestation. Subjects had sta-
ble or declining FEV1 on stable or decreasing immunosuppres-
sion. Twenty patients have been enrolled. One withdrew prior
to treatment and one withdrew after study medication initiation;
16/20 patients have reached the primary endpoint (6 months) on
study medication (10 mg qhs). Study participants age ranged
from 15-64 years, 12/20 female, with baseline FEV1 from 24
to 73% predicted. All patients met criteria for response on the
clinical trial with less than 15% decline in FEV1 % predicted
at the primary endpoint. FEV1 increased 5-13% predicted in 5
participants, remained stable in 6 (change \5%), and declined
5-13% in 5. Comparison of patient pre-study FEV1 decline to
on-study FEV1 values was generated using the slope of FEV1
volume vs. days post-transplant. The difference in pre- and pri-
mary endpoint slope revealed: 14/16 improvement and 2/16 de-
cline. Six minute walk test demonstrated that 4/16 patients had
significant increases in walk distance that exceeded the minimally
important difference, 2 of which had declining FEV1%. 2/20 had
a significant decline in walk test accompanied by a decline in
FEV1% predicted. Of 10 patients eligible for the 2 year end-
point, 7/10 are alive with 2 patients with durable FEV1 improve-
ments from baseline (FEV1+ 6%, +14%), 2 stable (FEV1 0%,
+1%), 3 with decline from baseline (FEV1 -4%, -4%, -8%).
Montelukast was well-tolerated with only one grade II probable
attributable adverse event (insomnia) during the six-month collec-
tion period. These findings suggest that montelukast is a promis-
ing therapy for BOS after allogeneic HSCT.429
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Aim: The immunological parameters governing the presentation
pathways for allogeneic peptides to induce graft-versus-host disease
(GVHD) are unclear. This is critical for the development of clinical
therapies based on antigen presentation to control deleterious allor-
eactive responses.
Method and Result: We developed a GVHD model following
a bone marrow transplant (BMT) system whereby presentation
of a processed recipient peptide within MHC class II can be spa-
tially and temporally quantified. The presentation of peptide
within MHC class II by recipient antigen presenting cell (APC)
resulted in GVHD mortality within ten days. While donor
APC could induce lethal acute GVHD, recipient APC were
100-1000 times more potent. Antigen presentation by recipient
APC resulted in accumulation of antigen-specific T cells within
